Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00124904 |
Fecal incontinence affects 2% of adults in the United States. Biofeedback has been recommended for the treatment of fecal incontinence because uncontrolled studies over the past 25 years suggest that these treatments are as effective as medical or surgical management and involve no risk. However, placebo-controlled trials are still lacking.
The aims of this study are: (1) to compare biofeedback to alternative therapies for which patients have a similar expectation of benefit; (2) to identify which patients are most likely to benefit; and (3) to assess the impact of treatment on quality of life.
Condition | Intervention |
---|---|
Fecal Incontinence |
Behavioral: Biofeedback Behavioral: Kegel exercises |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Biofeedback for Fecal Incontinence and Constipation |
Estimated Enrollment: | 165 |
Study Start Date: | September 1999 |
Estimated Study Completion Date: | December 2006 |
Study I is a long-term, prospective, single-blind study comparing biofeedback for fecal incontinence to a standard therapy (Kegel exercises) that is associated with a similar expectation of improvement (i.e., comparable placebo effect). Prior to randomization, patients will receive medical therapy (antidiarrheal medications as appropriate) and education for 4 weeks, and only patients who remain incontinent will be randomized. Anal canal squeeze pressures and rectal sensory thresholds will be tested before and after treatment. Patients will keep a diary throughout baseline and treatment, and they will be re-assessed at 3, 6, and 12 months. Treatment will consist of 6 clinic visits at 2-week intervals. The primary outcome is the patient's response to the question, "Have you had satisfactory relief of fecal incontinence (yes/no)?" This question is asked at 3 months following the end of treatment and at each follow-up visit. The investigators will develop a detailed treatment manual for fecal incontinence which would permit other investigators to replicate our study.
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, North Carolina | |
University of North Carolina Department of Medicine | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | William E Whitehead, PhD | The University of North Carolina, Chapel Hill |
Study ID Numbers: | RO1 DK57048a |
Study First Received: | July 27, 2005 |
Last Updated: | January 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00124904 |
Health Authority: | United States: Federal Government |
Biofeedback Incontinence |
Signs and Symptoms Fecal Incontinence Digestive System Diseases Urologic Diseases Urination Disorders |
Gastrointestinal Diseases Constipation Urinary Incontinence Intestinal Diseases Rectal Diseases |
Urological Manifestations |